Background. The association between combination antiretroviral (cARV) therapy use by human immunodeficiency virus (HIV)-infected women during pregnancy and risk of prematurity is still controversial. We explored this question, focusing on the initiation of ritonavir-boosted protease inhibitors (PIs) during pregnancy, which is now standard care.
Background. The association between combination antiretroviral (cARV) therapy use by human immunodeficiency virus (HIV)-infected women during pregnancy and risk of prematurity is still controversial. We explored this question, focusing on the initiation of ritonavir-boosted protease inhibitors (PIs) during pregnancy, which is now standard care.
Methods. Trends in prematurity (,37 gestational weeks) were studied among all singleton pregnancies in the Agence Nationale de Recherche sur le SIDA (ANRS) French Perinatal Cohort from 1990 through 2009 (n 5 13 271). In-depth analysis was conducted in a more detailed substudy of the cohort, among women starting PI-based ARV therapy during pregnancy (n 5 1253). Multivariable analysis adjusted for immunovirological status and known risk factors for prematurity.
Results. Prematurity increased from 9.2% during 1990-1993 (no therapy) and 9.6% during 1994-1996 (mostly zidovudine monotherapy) to 12.4% during 1997-1999 (dual-nucleoside analog therapy) and 14.3% during 2005-2009 (routine cARV therapy; P , .01). Prematurity was associated with cARV therapy, compared with zidovudine monotherapy, with an adjusted odds ratio of 1.69 (95% confidence interval [CI], 1.38-2.07; P , .01) when accounting for maternal age, intravenous drug use, geographic origin, and CD4 cell count. During 2005 During -2009 , the prematurity rate was higher with boosted than with nonboosted PI therapy started during pregnancy (14.4% vs 9.1% [P 5 .05] ; adjusted hazard ratio, 2.03 [95% CI, 1.06-3.89; P 5 .03] in multivariate analysis). The difference concerned mainly induced preterm delivery for maternal or fetal indications (5.6% vs 1.6%; P 5 .02),
Conclusions. The prematurity rate among HIV-infected pregnant women was twice that in the general population in France; this was not entirely explained by sociodemographic characteristics. Prematurity was independently associated with cARV therapy and, particularly, with the initiation of ritonavir-boosted PI therapy during pregnancy.
The use of antiretroviral (ARV) treatment regimens during pregnancy has led to a decrease in mother-to-child transmission of human immunodeficiency virus (HIV) type 1 to 1% in industrialized countries [1] . Since 1994, the standard of care has changed from zidovudine monotherapy to dual-nucleoside reverse-transcriptase inhibitors (NRTIs) and to triple-combination ARV regimens [2] .
There is ongoing concern about ARV-related toxicity to the mother and/or the developing fetus [3] [4] [5] [6] [7] . Adverse effects could be reflected in poor pregnancy outcomes, including preterm delivery. In a previous study [8] , we found no association between ARV and in utero growth restriction. The relationship between ARV and preterm delivery is a topic of controversy. A strong relationship between ARV and preterm delivery has been consistently reported in European cohorts [9] [10] [11] [12] [13] and in 1 American study [14] but was not found in most American studies [15] [16] [17] . Most studies failed to adjust for premature birth risk factors, such as socioeconomic conditions, access to care, obstetrical history, infertility treatments, body mass index, or smoking.
Indication bias was a problem in all of these studies. Because guidelines and practice changed over time, with regard to both the mother's own health and prevention of in mother-to-child transmission, the same ARV had different indications during different periods. Adjusting for CD4 cell counts or viral loads was insufficient to account for these biases because they result not only from baseline characteristics but also from a treatment effect dependant on duration, thus differing between term and preterm deliveries.
The most puzzling aspect of the controversy is the lack of a plausible biological mechanism, whereby ARV therapy might increase the risk of preterm delivery. Fiore et al suggested that the influence of ARV therapy on the T-helper 1/T-helper 2 cytokine shift may be implicated, but this hypothesis has not been confirmed [18] .
Finally, because of the small numbers of patients, no study was able to investigate preterm delivery with respect to specific drugs, in particular ritonavir-boosted protease inhibitors (PIs), which are now standard care. Ritonavir is a potent inducer or inhibitor of several P450 cytochromes and interacts with adrenal enzymes through the inhibition of CYP3A4, which is involved in glucocorticoid metabolism [19] . This may be important because maternal and fetal adrenal axes are implicated in spontaneous preterm birth outside the context of HIV infection and therapy [20] , even though the mechanisms involved are not fully understood.
The objectives of our study were (1) to study trends in prematurity between periods with different types of standard care and (2) to evaluate factors and attempt to identify potential mechanisms associated with preterm birth among patients starting PI-based ARV therapy during pregnancy. We also distinguished spontaneous from induced preterm births and identified the pregnancy complications that led to these outcomes.
METHODS

French Perinatal Cohort (EPF; ANRS CO1/CO11)
Since 1986, EPF has prospectively enrolled pregnant HIVinfected women delivering at 90 centers throughout France [21] . EPF is a cohort funded by the ANRS (Agence Nationale de Recherche sur le SIDA) that includes several components. The CO1 and CO11 components focus on pregnant women and were used in this study. Informed consent was obtained from all mothers. Clinicians were encouraged to follow regularly updated French national guidelines [2, 22] . The study was approved by the Hô pital Cochin institutional review board and the French computer database watchdog commission.
Overall Study Population, 1990 Population, -2009 Trends in the incidence of preterm delivery from 1990 through 2009 and their relation to the type of ARV therapy were studied in all singleton births, including stillbirths and terminations of pregnancies, occurring beyond 22 weeks gestation (n 5 13 271) (Figure 1 ).
Substudy Population: PI-Based Combination ARV Therapy Initiated During Pregnancy, 2005 Pregnancy, -2009 We performed an in-depth analysis among the singleton births from 2005 through 2009 for mothers enrolled in the EPF-CO1 component of the cohort, which recorded more detailed data. Exclusion criteria are presented in Figure 1 . The choice of restricting the substudy to women starting PI-based regimens during pregnancy was made to reduce treatment bias and because it corresponded to a relevant clinical situation that induces rapid immunovirological changes and potential unexpected adverse effect. We retained the last pregnancy for women who had several pregnancies in the study period. The analysis thus included 1253 births. We also selected a second substudy population including the 1094 births that occurred during the previous period, 2000-2004, according to the same algorithm as that used for the in-depth substudy analysis (Figure 1 ), for which only the crude association of preterm birth with boosted versus nonboosted PI was studied.
Variables
Preterm delivery was defined as those occurring before 37 weeks gestation, and very preterm delivery was defined at ,32 weeks. Gestational age was determined from the last menstrual period, corrected, if necessary, according to the first-trimester ultrasound. All preterm births during 2005-2009 were classified into 2 groups: (1) spontaneous prematurity after either preterm labor or preterm premature rupture of membranes or (2) induced prematurity resulting from induction of labor or cesarean section after maternal or fetal complications other than preterm premature rupture of membranes.
Obstetrical complications were recorded specifically (preeclampsia, gestational diabetes, bleeding, and hospitalization) or in open questions (cause for hospitalization and other medical conditions during pregnancy). Liver toxicity was defined by elevated liver enzyme levels on a standardized scale [23] .
All ARV combinations were recorded with dates at initiation and end. For the overall analysis, ARV combinations were classified as NRTI monotherapy, NRTI dual therapy, or combination ARV (cARV) therapy, defined as a combination containing $3 drugs or at least a PI or a nonnucleoside reversetranscriptase inhibitor (NNRTI). For the substudy population, PI-based ARV was defined as boosted if ritonavir was included. Ritonavir was never used as the sole PI.
Sociodemographic, clinical, and other obstetrical characteristics were collected. Gestational age at first visit to the obstetrical center was used as a marker of their level of access to care. Characteristics of HIV disease included date of diagnosis, primary infection during pregnancy, highest Centers for Disease Control and Prevention (CDC) clinical category [24] , and all viral load and CD4 cell counts during the pregnancy. We also recorded hepatitis C coinfections, defined as Figure 1 . Study population. Since 2005, the French Perinatal Cohort has been divided into 2 components. The CO1 component includes women from the largest maternity wards (two-thirds of total enrollment) and collects very detailed sociodemographic, clinical, and biological information. The CO11 component includes the smaller maternity wards and collects less-detailed information. FI, fusion inhibitor; GA, gestational age; NRTI, nucleoside reverse-transcriptase inhibitor; NNRTI, nonnucleoside reverse-transcriptase inhibitor; PI, protease inhibitor.
active if polymerase chain reaction test results were positive. Obstetrical complications, pretherapeutic blood tests and detailed sociodemographic variables were not available before 2005 or for the CO11 component of the cohort.
Statistical Methods
The rates of preterm birth were described throughout the 1990-2009 period. For the overall study, associations between preterm birth and type of ARV were performed using logistic regression models. Odds ratios (ORs) were adjusted systematically for time at ARV therapy initiation and for the following potential confounders (selected because they were used in the literature and were available for the whole period during 1990-2009): intravenous drug use, ethnic origin, maternal age at delivery, and CD4 cell count at delivery. To allow for repeated pregnancies in the same woman, generalized linear mixed effects were used to fit logistic regression models accounting for random effects attributed to the mother [25] .
In the substudy (2005-2009), we first compared characteristics of women who started ritonavir-boosted PI with those of women who started nonboosted PI therapy during pregnancy. We then compared these 2 groups for the rates of preterm and very preterm delivery and for the frequency of obstetrical complications using v 2 and Fisher's exact tests, as appropriate, to determine statistical significance. Risk factors for premature birth were analyzed using survival analyses (Kaplan-Meier and the Cox proportional hazard model), generating adjusted hazard ratios (aHRs), in which induced prematurity was considered as an event to study overall prematurity (ie, all preterm births), or censored at the date of delivery to study spontaneous prematurity. Boosted versus nonboosted PI was used as a time-varying variable. Time was truncated at 37 weeks gestation for all patients. Repeated pregnancies were excluded from this substudy to perform survival analysis. The initial model was adjusted for factors found to be associated with prematurity in bivariable analyses (P , .20) or known to be risk factors for prematurity. A parsimonious model was obtained after excluding variables not known to be risk factors for prematurity and variables for which P ..05 in the initial model. Sensitivity analyses were conducted by varying different parameters for the association between prematurity and ARV type. Data were analyzed using Stata software, version 11.0 (StataCorp) [26] .
RESULTS
Overall Study: 1990 Study: -2009 The overall prematurity rate increased significantly from 9.2% during 1990-1993 to 14.3% during 2005-2009 (Figure 2 and Supplementary Material Table A ). Characteristics of the women receiving ARV therapy during pregnancy are presented in Table 1 .
Among them, the risk of prematurity was lower with zidovudine alone than with NRTI dual therapy or cARV therapy (P , .001) (results shown in Table 2 ). The association with cARV therapy remained significant after adjustment for potential confounders mentioned above (adjusted OR,1.69; 95% confidence interval [CI], 1.38-2.07). The risk of prematurity was higher among women already being treated at conception, compared with women whose treatment began during pregnancy, regardless of ARV therapy type (adjusted OR, 1.31; 95% CI, 1.11-1.55; P 5 .001). The other factors except geographic origin also remained independently associated. The majority of this group of 1253 women were from subSaharan Africa, multiparous, and ARV therapy naive and had started treatment during the second trimester (Table 3) . Among all PI-based ARV therapy regimens, 85% were ritonavir boosted (1066 of 1253). The boosted PI most frequently used was lopinavir (81%), and the most frequently used nonboosted PI was nelfinavir (92%) (Supplementary Material Table B ). Women receiving boosted (vs nonboosted) PIs had less illicit drug use or smoking, first visited the obstetrical center at a later gestational age, and were more likely to deliver in the 2007-2009 period but did not differ in any characteristic of their HIV infection ( Table 3) .
The prematurity rate was 13.6% (170 of 1253; 95% CI, 11.7%-15.5%), higher in case of boosted (14.4%; 153 of 1066) than nonboosted PI therapy (9.1%; 17 of 187) although it did not reach significance (P 5 .053). The rate of severe prematurity was 2.7% (28 of 1253; 95% CI, 1.8%-3.6%) and was similar for the 2 groups (2.8% vs 2.1%, P 5 .60). The prematurity rate was homogeneously higher among the boosted PIs than for the nonboosted PIs (Supplementary Material  Table C ). Cox model analysis for overall prematurity is shown in Table 4 . In the initial multivariable model, premature birth remained significantly associated with boosted-PI, compared with nonboosted PI (aHR, 2.03; 95% CI, 1.06-3.89; P 5 .03). The association remained of the same magnitude (aHR, 1.76; 95% CI, .97-3.19; P 5 .06) in a more parsimonious model that excluded hepatitis C infection, viral load, and time of initiation of treatment. Early first visit at the obstetrical center, marital status, and CDC stage were also significantly associated with prematurity.
The type of prematurity differed according to boosted or nonboosted PI use ( Table 5 ). The main reasons for induced prematurity are presented in Table 5 . Spontaneous prematurity represented 61% of total prematurity. Spontaneous prematurity was not significantly associated with boosted PI in the multivariable Cox model, in which induced premature births were censored at the date of delivery (aHR, 1.51; 95% CI, P 5 .27) .
Pregnancy complications were more frequent in women receiving boosted PIs ( Table 5 ). All of the complications described were significantly associated with prematurity (results not shown).
Neonatal complications did not differ according to boosted or nonboosted PI use. Rates for neonatal hospitalizations (8% vs 9%; P 5 .86), respiratory distress (3% vs 4%, P 5 .68), neurological symptoms (2% vs 3%; P 5 .87), and birth weight (Z score, 20.14 vs 20.2; P 5 .49) were similar for both groups.
Association Between Premature Birth and Boosted Versus Nonboosted PIs: Sensitivity Analyses
We first restricted the multivariable Cox model to various subpopulations (primiparous mothers, non-drug users, women naive for ARV therapy, HIV nontransmitters, and live births); the aHRs remained of the same magnitude, although they did not always reach significance (additional Material Online Table  D) . Finally, among the 1094 cases selected from the previous period (2000) (2001) (2002) (2003) (2004) , results of bivariable analysis were very similar to those for [2005] [2006] [2007] [2008] [2009] . The overall prematurity rate was 13.2% (144 of 1094). The proportion of ritonavir-boosted PIs initiated during pregnancy was lower (376 [34%] of 1094), but the differences between boosted and nonboosted PIs were significant for all premature births (16.0% vs 11.7%; P 5 .05) and for severe prematurity (4.0% vs 1.8%; P 5 .03).
DISCUSSION
Our findings suggest a relationship between cARV use and preterm delivery. First, the preterm rate in the EPF cohort increased over a 20-year period. The current rate (13.6%) was markedly higher than in the general French population (5.8%) [27] . Preterm delivery rates well above national rates have also been reported by HIV perinatal cohorts in the United Kingdom, Ireland [11] , and the United States [14, 17, 28] . Furthermore, we found that the use of cARV therapy during pregnancy was a highly significant risk factor, even after adjusting for other factors known to increase the risk of preterm delivery. These findings are consistent with mounting evidence in Europe for a relationship between ARV therapy use and premature birth [9] [10] [11] [12] [13] 29] and have been recently described in a randomized study in Africa [30] but conflict with several studies performed in the United States [15] [16] [17] that found no such relationship. The differences may be attributable simply to chance or to variability in the numbers of patients studied, but there may be real differences between countries and between periods with respect to the populations studied, confounding risk factors, and drug regimens used. Our study is the largest to focus on a homogenous population starting routine standard-care PI-based ARV therapy and allows for adjustment of factors known to be associated with prematurity in the general population [20, 31] . These factors, such as smoking and maternal age, were also associated with prematurity in our population. In addition, women with Abbreviations: ANRS, Agence nationale de recherche sur le SIDA; ARV, antiretroviral; BMI, body mass index; CDC, Centers for Disease Control and Prevention; HCV, hepatitis C virus; HIV, human immunodeficiency virus; PI, protease inhibitor; PMTCT, prevention of mother-to-child transmission; TOP, termination of pregnancy. a Hospitalization for vascular or metabolic cause includes preeclampsia, diabetes, hypertension, proteinuria; vascular or metabolic problem includes all causes cited above with hospitalization, as well as preeclampsia and diabetes without hospitalization. b Total sample corresponding to patients who had blood tests before initiation of treatment: 845, 724, and 121 patients, respectively. a history of AIDS-defined illness had a higher risk of preterm delivery than women who did not, even after adjustment in multivariable analysis. However, of interest, although the maternal CD4 cell count correlated with the risk of premature birth in the overall cohort population, this relationship was not significant in the women who started cARV therapy during their pregnancy during the [2005] [2006] [2007] [2008] [2009] period. This suggests that the relationship between HIV infection and premature birth cannot be attributed to only the severity of the immunodeficiency. Our most important finding was a significant association between prematurity and ritonavir-boosted PI therapy, compared with nonboosted PI-based therapy. This could not be explained by differences in the characteristics of the mothers in the 2 groups. Ritonavir is associated with complex metabolic changes and could interfere with the adrenal systems of both the mother and the fetus through its interactions with CYP3A4 [19] . Recently, transient adrenal dysfunction was reported for neonates exposed to ritonavir-boosted PIs both in utero and after birth [32] . Because these adrenal systems are involved in the spontaneous onset of labor [20] , ritonavir-boosted PIs may influence its timing. To date, no study has specifically examined the effects of boosted PIs, compared with nonboosted PIs, on premature birth. Patel et al and Tuomala et al found no significant differences in the rate of prematurity associated with PI-based treatments, compared with non-PI-based treatments [16, 17] . However, in both of these studies, most of the PI treatments used were nonboosted. In other studies, whether the PI was ritonavir boosted or not was not specified.
We found that boosted PI was more strongly associated with induced than with spontaneous premature birth. Pregnancy complications, including preeclampsia, gestational diabetes, and liver toxicity, were associated with induced prematurity and were also significantly more frequent in the boosted than nonboosted PI group. The medical decision to deliver may account for part of the increase in mild prematurity. Gestational complications have not been investigated previously with respect to the use of ritonavir-boosted PIs. PIs are known to increase insulin resistance in adults, including pregnant women, although the incidence of gestational diabetes mellitus may be only slightly increased [7, 33] . Some studies have suggested that there may be a relation between PI-based ARV therapy and low birth weight or preeclampsia [34] . Wimalasundera et al and Suy et al [5, 6] hypothesized that immune restoration might be involved in preeclampsia. Although some studies have reported an increased risk of low birth weight in association with ARV therapy, this was not the case in our cohort [8] .
Although ARV therapy was more strongly related to induced prematurity, we also observed a trend for spontaneous prematurity. The aHR for boosted PI-based ARV therapy and spontaneous prematurity was 1.5; however, it did not reach statistical significance, possibly because of lack of power. Of interest, there were more hospitalizations for threatened preterm labor in the boosted PI group. The study by Patel A Cox proportional hazards model was used. Premature birth was defined as birth at ,37 weeks gestation. a Ritonavir-boosted PI treatment was used as a time-varying variable in the model.
et al [17] was the only previous analysis to differentiate spontaneous from overall premature births. Although the ORs associated with PI treatment were higher for all preterm births than for spontaneous preterm births alone, neither was statistically significant. Our study presents several advantages over previous studies. Detailed information was available for premature birth risk factors, HIV status, ARV type, and pregnancy care. Pretherapeutic viral load and CD4 cell count data allowed us to adjust for treatment indication, whereas prior studies used measures at delivery that depend on the duration of therapy and, thus, on gestational age at birth.
Our study also has some limitations. We cannot rule out differences cause by the PI, lopinavir or nelfinavir, rather than the ritonavir boost, although the prematurity rate was homogenously higher for all the boosted PIs than it was for nelfinavir. It would have been useful to compare PI-based treatments with NNRTI-based treatments or cARV therapy with monotherapy or dual therapy, but the numbers of patients in the cohort during the 2005-2009 period were insufficient for these comparisons. Finally, much of the increase in premature birth occurred during 1997-1999, a period during which boosted-PI therapy was not yet predominant. This might suggest that the efficacy of therapy, rather than the type of cARV therapy, might be the main correlate with prematurity, as has been suggested elsewhere [35] . This could possibly be explained by the phenomenon of immune restoration. The association between premature birth and boosted PI therapy cannot be entirely attributed to an action on the adrenal system, which would be expected to influence spontaneous prematurity more than induced prematurity.
In conclusion, we found a higher rate of prematurity associated with boosted PI, compared with nonboosted ARV, which was independent of other risk factors. Patients receiving ritonavir had more maternal metabolic and vascular complications, leading to an increase in induced premature births. Although a causal Abbreviations: Vascular or metabolic problem, includes preeclampsia, diabetes, hypertension, proteinuria; FHR, fetal heart rate; IUGR, intrauterine growth restriction; PI, protease inhibitor; TOP, termination of pregnancy. a Listed as main cause of hospitalization, these categories are mutually exclusive in the statistical analysis.
b P value determined by overall v 2 test (2 df) comparing prematurity in 3 categories (none, induced, spontaneous) according to boosted or nonboosted-PI.
relationship cannot be confirmed, our findings suggest a plausible explanation for the association between cARV therapy and prematurity that merits further investigation. Because boosted PI therapies are standard care during pregnancy, this may have important clinical implications.
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